ERBB2 and ovarian carcinoma: who engineered miR-200c and trastuzumab (TZ)-loaded nanoparticles that dual-target critical pathways driving SKOV3 cell survival and proliferation in vitro, overcoming TZ resistance while potentially improving therapeutic outcomes for HER2-positive ovarian cancer (126).